help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaquette, J.
Right arrow Articles by Segaloff, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaquette, J.
Right arrow Articles by Segaloff, D. L.
Endocrinology Vol. 138, No. 1 85-91
Copyright © 1997 by The Endocrine Society


ARTICLES

Temperature Sensitivity of Some Mutants of the Lutropin/Choriogonadotropin Receptor1

Julie Jaquette and Deborah L. Segaloff2

Department of Physiology and Biophysics, The University of Iowa College of Medicine, Iowa City, Iowa 52242

Address all correspondence and requests for reprints to: Deborah L. Segaloff, Ph.D., Department of Physiology and Biophysics, The University of Iowa College of Medicine, Iowa City, Iowa 52240.


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The lutropin/choriogonadotropin receptor (LHR) is a G protein-coupled receptor central to reproductive physiology. In addition to the complex structure formed by seven membrane-spanning helices, this receptor also contains a large amino-terminal domain whose tertiary structure is unknown. Many mutations of this receptor result in partial or complete intracellular retention of the mutant, regardless of whether the mutations are located in the extracellular domain, interhelical loops, transmembrane helices, or cytoplasmic tail. Nonetheless, as long as a mutation has not disturbed a hormone binding site, the intracellularly trapped mutant retains high affinity binding for human CG (hCG), suggesting that it is not extremely misfolded. Because temperature is known to affect protein folding, we examined the effects of reduced temperature on cell surface expression of intracellularly retained mutants of the LHR. Our studies examined three different 293 cells lines, each stably expressing a different LHR mutant that is intracellularly retained at 37 C. The results presented demonstrate that preincubation of the cells for 48 h at 26 C markedly increased both the total hCG binding activity within each cell line as well as the percentage of binding activity at the cell surface. Furthermore, the cells bound hCG with a normal high affinity and responded to hCG with increased cAMP production normally. These data suggest that decreased temperatures can allow partially misfolded LHRs to fold properly and be expressed in functional form on the cell surface and thus present the potential for utilization of this approach for other intracellularly retained G protein-coupled receptor mutants.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
THE LUTROPIN/CHORIOGONADOTROPIN RECEPTOR (LHR) is a member of the superfamily of G protein-coupled receptors. This receptor, present on cells in the testes and ovaries binds either pituitary LH or placental CG. The cellular response to the binding of hormone to the LHR is a stimulation of adenylyl cyclase activity and (at relatively high concentrations of hormone) an activation of phospholipase C (1). Like other G protein-coupled receptors, the LHR contains the classical feature of seven hydrophobic regions that transverse the plasma membrane (2). Unlike the adrenergic receptors, which are widely considered the paradigm of G protein-coupled receptors, however, the LHR contains a large amino-terminal domain (2). Studies by ourselves and others have shown that this extracellular domain is sufficient for conferring high affinity binding and appropriate binding specificity (3, 4, 5, 6).

In the course of mutagenesis studies of the rat LHR (rLHR), it has been found that many mutations of the rLHR result in an intracellular retention of the receptor (Refs. 7–14 and unpublished observations). Interestingly, as long as a region involved in hormone binding has not been disturbed, the intracellularly trapped mutant receptors bind human CG (hCG) with high affinity if the cells are first solubilized with detergent (Refs. 7–14 and unpublished observations). As such, it has been possible to assess the relative degree of intracellular retention of various LHR mutants by comparing the hCG binding activity of intact cells (representing cell surface receptors only) with the binding activity of detergent solubilized extracts (representing both cell surface as well as intracellular receptors) (9, 10, 11, 12, 13). Cells expressing the wild-type rLHR express greater than 70% of the total hCG binding activity on the cell surface (Refs. 7–14 and unpublished observations). Mutations of the rLHR have been found to have varying effects on cell surface expression. Whereas many mutants are expressed at normal levels at the cell surface (12, 15), some are trapped to moderate degrees intracellularly (9, 10, 16), and others are barely detectable at the cell surface (7, 13).

It has recently been shown that the most widely occurring mutations of the cystic fibrosis transmembrane regulator (CFTR) result in intracellular retention of this multimembrane spanning chloride channel (17). Furthermore, it has been demonstrated that incubation of cells expressing certain intracellularly retained CFTR mutants at reduced temperatures increases the percentage of CFTR protein at the cell surface (18). Because this approach has not been previously examined with mutant G protein-coupled receptors, the following studies were undertaken to examine whether reduced temperatures would similarly be an effective means of increasing the expression of mutant intracellularly retained LHRs at the plasma membrane.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Cells expressing wild-type and mutant LHR cDNAs
The full-length wild-type rLHR in pcDNA/neo I and the mutants rLHR(K541, 544, 547A) and rLHR(T175A) have been previously described by us (2, 9, 12). The mutant rLHR(E441Q) was described by Ascoli and co-workers (10). Nonclonal human embryonic kidney 293 cells stably expressing rLHR(E441Q) and rLHR(wt-18) cells, a clonal line of 293 cells stably expressing the wild-type LHR, were generously provided by Dr. Mario Ascoli (The University of Iowa). Clonal 293 cells stably expressing rLHR(K541, 544, 547A) were previously described by us (9) and are referred to herein as rLHR(K541, 544, 547A-c1) cells. Clonal rLHR(T175A-c1) cells stably expressing rLHR(T175A) were prepared for these studies using methods described elsewhere (10). All cells were maintained in growth medium (DMEM) containing 50 µg/ml gentamicin, 700 µg/ml G418, and 10% newborn calf serum) in humidified atmosphere containing 5% CO2.

Temperature shift experiments
For temperature shift experiments, cells were plated onto 60-mm dishes that had been preincubated 45 min at room temperature with 50 µg/ml fibronectin. Newly plated cells were incubated for 24 h in growth media in a 37 C humidified incubator containing 5% CO2. Forty-eight hours before an experiment, cells were transferred to modulator incubator chambers filled with a humidified mixture of 95% 02 and 5% CO2, which was then placed in ungassed incubators at 37 C (control group), 30 C, or 26 C.

Determination of 125I-hCG binding activity at the cell surface
125I-hCG binding assays were performed on intact cells to determine the maximal binding capacity of cell surface receptors (A) and on detergent soluble extracts of cells to determine the maximal binding capacity of total (i.e. both cell surface and intracellular) receptors (B). The percentage of hCG binding activity on the cell surface was determined as A/B x 100. 125I-hCG binding to intact cells was performed as described previously (9), where cells were incubated overnight at 4 C with a saturating concentration (100 ng/ml) of 125I-hCG in the absence or the presence of an excess of unlabeled hCG (50 IU/ml). The preparation of detergent soluble extracts of cells and 125I-hCG binding to the soluble extracts has been previously described (9). Aliquots of the detergent soluble extracts were incubated overnight on ice with a saturating concentration (100 ng/ml) of 125I-hCG in the absence or the presence of an excess of unlabeled hCG (50 IU/ml). Soluble binding assays were completed by filtration on polyethyleneimine-treated filters (19). All measurements were performed in duplicate.

Determination of equilibrium binding constants
Intact cells were incubated with a subsaturating concentration of 125I-hCG in the presence of increasing concentrations of unlabeled hCG overnight at 4 C as previously described (9). All measurements were performed in duplicate. The data were analyzed using the computer program LIGAND (20) to calculate the equilibrium binding constants.

cAMP assays
For these experiments, cells were plated on fibronectin-coated 35-mm wells. After 48-h preincubations at 37 C or 26 C, the cells were washed two times with 2 ml of warm Waymouth MB752/1 media containing 50 µg/ml gentamycin and 1 mg/ml BSA and placed in 1 ml of the same medium containing 0.5 M isobutylmethylxanthine. After 15 min at 37 C, increasing concentrations of hCG were added and the incubation was continued for 60 min at 37 C. The cells were then placed on ice, and the total cAMP accumulated (in the cells and media) was extracted by the addition of 1 ml 2 N perchloric acid containing 360 µg/ml theophylline and then measured by RIA. All measurements were performed in triplicate. The curve describing the best fit of the data and the calculations of the EC50 (the concentration of hCG required to elicit half-maximal cAMP production) and Rmax (the maximal amount of cAMP produced) were determined using the computer program Delta Graph.

Hormones and supplies
Highly purified hCG was kindly provided by the National Hormone and Pituitary Agency of the NIDDK/NIH and was iodinated as described previously (21). Modulator incubator chambers were obtained from Billups-Rothenberg (Del Mar, CA).


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
To test the hypothesis whether growth of cells expressing such mutants at reduced temperatures would increase the percentage of receptors at the cell surface, we initially chose to examine three different rLHR mutants: rLHR (K541, 544, 547A) in which three lysine residues within the carboxyl region of the third intracellular loop have been simultaneously mutated to alanines (9); rLHR(T175A) in which a threonine residue within a potential site of N-linked glycosylation on the extracellular domain of the receptor has been mutated to alanine (12); and rLHR(E441Q) in which a highly conserved acidic residue at the interface between the third transmembrane helix and the second intracellular loop has been substituted with glutamine (10). Previous studies have shown that although the majority of each of these mutants is retained intracellularly, solubilized extracts from cells expressing each of the mutants binds hCG with a high affinity comparable with the wild-type receptor alanines (9, 10, 12). Therefore, although each of these mutations must cause a perturbation in the conformation of the receptor, resulting in its intracellular retention, the mutations are not affecting a hormone binding site. We thus chose these three rLHR mutants for this study because they do not disrupt a hormone binding site and because each mutant is retained to a different degree intracellularly.

Because intracellular forms of the wild-type rLHR or mutant rLHRs maintain high affinity hCG binding, hCG binding assays to solubilized cells can be used to measure the sum of intracellular plus cell surface receptor. By comparing this with data obtained from hCG binding assays to intact cells, which measures only cell surface receptors, it is possible to calculate the percentage of rLHR present on the cell surface. As shown in Table 1Go, when cells expressing the wild-type LHR were preincubated for 48 h at 37 C before the hCG binding assays (which are performed at 4 C), 93% of the receptor was at the cell surface. In contrast, 37 C preincubated cells expressing either rLHR(K541, 544, 547A), rLHR(T175A), or rLHR(E441Q) expressed only 40%, 34%, and 15% of the receptor at the cell surface, respectively. The effects of decreased temperature on rLHR expression were determined by comparing cells preincubated for 48 h at 37 C with those preincubated for 48 h at 30 C or 26 C before assaying for hormone binding. As seen in Table 1Go, for all the cell lines examined, the total amount of 125I-hCG binding activity was increased approximately 3-fold by preincubating the cells at either 30 C or 26 C, as compared with 37 C. In spite of the increase in the total number of receptors at 30 C and 26 C, the percentage of binding activity at the cell surface for the wild-type receptor was not increased at the reduced temperatures. In contrast, the proportion of 125I-hCG binding activity on the cell surface for each of the three mutants examined increased significantly at the reduced temperatures. Thus, whereas only 40% of rLHR(K541, 544, 547A) was at the cell surface after a 37 C preincubation, greater than 70% was on the cell surface after 30 C or 26 C preincubations. Similarly, whereas 34% of rLHR(T175A) was on the cell surface after a 37 C preincubation, 61% and 78% were on the cell surface after 30 C and 26 C preincubations, respectively. Although, the expression of rLHR(E441Q) was also shifted to the cell surface, the magnitude of the shift was not as great as with the other two mutants. Thus, rLHR(E441Q), which expressed only 15% of its receptors at the cell surface after preincubation at 37 C, increased its cell surface expression to 27% and 44% after 30 C and 26 C preincubations, respectively. The data shown in Table 1Go also show that preincubations of the cells expressing the mutant receptors at 26 C were more effective than preincubations at 30 C. In other experiments (not shown), it was determined that although increases in cell surface expression of the mutants was apparent after 24 h at 26 C, they were not as great as those observed after a 48-h preincubation. Furthermore, a 72-h preincubation at 26 C was as effective as a 48-h preincubation but led to a greater loss of cell viability. Therefore, the optimal conditions for maximizing cell surface expression without jeopardizing cell viability were determined to be a 48-h preincubation at 26 C.


View this table:
[in this window]
[in a new window]
 
Table 1. 125I-hCG binding to 293 cells expressing wt-rLHR or rLHR mutants after 48-h preincubations at different temperatures

 
The results presented thus far clearly demonstrate that 26 C preincubations of cells expressing each of the three rLHR mutants increases the percentage mutant receptor at the cell surface. We next wished to determine whether the mutant receptors shifted to the cell surface after a 48-h preincubation at 26 C are functional, as determined by their ability to stimulate cAMP accumulation when incubated with hCG. These experiments are rather difficult to perform because one cannot readily compare the Rmax and EC50 from one cell line to another unless the cell lines express comparable num-bers of cell surface receptors. Therefore, we tested several different clones of cells expressing the wild-type rLHR, rLHR(K541, 544, 547A), and rLHR(T175). Because the cells expressing rLHR(E441Q) were nonclonal, it was not possible to test more than one set of cells for these. The clones expressing the most closely matched numbers of receptors are those that were used for the experiments shown in Table 1Go. As can be seen from that data, within these cell lines, only rLHR(K541, 544, 547A-c1) expressed similar numbers (albeit about half) of cell surface receptors as rLHR(wt-18) cells. For these reasons, the experiments assessing the functional properties of temperature shifted mutant receptors were performed on rLHR(K541, 544, 547-c1) cells, comparing them with rLHR(wt-18) cells.

Before assessing the functional properties of rLHR(K541, 544, 547A-c1) and rLHR(wt-18) cells after a preincubation at 26 C, we first tested whether the binding affinity of the wild-type or mutant receptor was altered by preincubation at reduced temperature. As shown in Table 2Go, intact rLHR(wt-18) cells bound hCG with a comparable affinity after a 48-h preincubation at 26 C as compared with cells preincubated at 37 C. Similarly, intact rLHR(K541, 544, 547A-c1) cells bound hCG with the same high affinity after a 26 C preincubation as after a 37 C preincubation. We next examined the ability of each of the cell lines to respond to hCG with increased cAMP after preincubations at 37 C vs. 26 C. After preincubating each group of cells for 48 h at either 37 C or 26 C, all cells were then incubated at 37 C in the absence of hormone or with increasing concentrations of hCG. As summarized in Table 3Go, when the cells were preincubated at 37 C, the Rmax of rLHR(K541, 544, 547A-c1) cells somewhat greater than that of rLHR(wt-18) cells and the EC50 values of the two cell lines were comparable. After a 48-h preincubation at 26 C, the Rmax and EC50 values for both the rLHR(K541, 544, 547A-c1) and rLHR(wt-18) cells were comparable with the same cell line preincubated at 37 C. These data suggest that at these receptor densities the Rmax is not proportional to cell surface receptor numbers. This conclusion is further supported by earlier studies comparing the responsiveness of rLHR(wt-18) cells as compared with a cell line expressing 4-fold higher numbers of cell surface wild-type rLHRs (11) and is consistent with the model put forth by Whaley et al. describing the relationship between Rmax and cell surface receptor numbers (22). The observation, however, that the responsiveness of the rLHR(K541, 544, 547A-c1) cells after the 26 C preincubation is as good, if not better, as compared with the rLHR(wt-18) cells after the 26 C preincubation suggests that the increased cell surface mutant receptors expressed after a 48-h preincubation of the cells at 26 C are capable of transducing the signal of hormone binding.


View this table:
[in this window]
[in a new window]
 
Table 2. Binding affinity of hCG to rLHR(K541,544,547A-c1) and rLHR(wt-18) cells after a 48-h preincubation at 37 C vs. 26 C

 

View this table:
[in this window]
[in a new window]
 
Table 3. hCG-stimulated cAMP production in rLHR(K541,544,547A-c1) cells and rLHR(wt-18) cells after a 48-h preincubation at 37 C vs. 26 C

 
The above results suggest that preincubations of cells expressing certain rLHR mutants at reduced temperatures can increase the density of functional cell surface receptors. As such, in many instances where the numbers of cell surface mutant receptors are too low to test the functional consequence of the mutation, a preincubation at reduced temperature might increase the percentage of receptor at the cell surface to allow for assays of their function. However, many of these experiments (such as measurements of hormone-stimulated cAMP or inositol phosphate production and receptor-mediated hormone internalization) require incubations of the cells at 37 C during the experiment. In order for these studies to be feasible, it is necessary to show that the increased expression of cell surface mutant receptors after a 26 C preincubation does not rapidly decrease upon reversion of the cells to 37 C. Therefore, the following experiment was performed to see how long the increased percentage of receptor at the cell surface would remain once the cells were placed back into a 37 C environment. It was difficult to use cells expressing rLHR(E441Q) for these experiments due to the low numbers of receptor in cells expressing this mutant. Therefore, rLHR(K541, 544, 547A-c1) and rLHR(T175A-c1) cells were tested for reversibility of cell surface expression. Of the two cell lines examined, a complete time course was performed for the rLHR(T175A-c1) cells and the data from these experiments are shown in Fig. 1Go. As shown in Fig. 1Go, a 48-h preincubation at 26 C resulted in 75% of the rLHR(T175A) being on the cell surface as opposed to only 19% if the cells were preincubated for the same length of time at 37 C. For control purposes, cells were also preincubated for 72 h at 26 C vs. 37 C. The same trend was apparent, where 100% of the mutant was on the cell surface after 3 days at 26 C vs. 20% of the mutant after 3 days at 37 C. To examine the time-course of reversibility, cells were preincubated at 26 C for 48 h and then shifted to 37 C for 2 h, 6 h, or 24 h. As shown in Fig. 1Go, the percentage of mutant receptor at the cell surface remained elevated even after 6 h of being returned to 37 C. However, by 24 h after being shifted back to 37 C, the percentage of mutant receptor at the cell surface was decreasing. Nonetheless, it was still elevated compared with cells having been at 37 C continuously. Similar results were observed for rLHR(K541, 544, 547A-c1) cells in that cells preincubated for 48 h at 26 C and then 6 h at 37 C showed a comparable percentage of cell surface receptors as cells preincubated for 48 h at 26 C only (data not shown). Taken altogether, these data show that although the effects of reduced temperature on cell surface expression of LHR mutants are reversible, the time course is slow enough to allow for most assays of receptor function.



View larger version (42K):
[in this window]
[in a new window]
 
Figure 1. Reversibility of the cell surface expression of a LHR mutant. rLHR(T175A-c1) cells were preincubated continuously for 48 h (two columns at extreme left) or for 72 h (two columns at extreme right) at 37 C or 26 C before assaying for cell surface vs. total hCG binding activity. Other cells (three columns with stippled bars) were preincubated for 48 h at 26 C and then returned to 37 C for 2 h, 6 h, or 24 h before assaying for cell surface vs. total hCG binding activity as described in Materials and Methods. Data shown are the mean ± SEM of three independent experiments.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Earlier studies with the vesicular stomatitis virus G protein demonstrated that G proteins with altered glycosylation sites were not apparent on the cell surface when the cells were grown at 37 C but were detected on the cell surface if the cells were grown at 30 C (23). Although there are other reports of decreased temperatures aiding in the folding of proteins, there are not many. Furthermore, in all but one case, the proteins do not span the plasma membrane multiple times. Interestingly, it has been demonstrated that the mutant CFTR protein most commonly associated with cystic fibrosis, CFTR({Delta}F508), (17) is temperature sensitive (18). Thus, it is detected on the cell surface in a functional form when expressed in Xenopus oocytes or Sf9 insect cells, which are typically grown at temperatures less than 37 C, but not in mammalian cells maintained at 37 C. However, if mammalian cells expressing the CFTR({Delta}F508) mutant are preincubated for 2 days at reduced temperatures, then functionally active CFTR protein is expressed at the cell surface (18). Because many mutations of the rLHR introduced by site-directed mutagenesis have also been shown to result in intracellular retention (Refs. 7–14 and unpublished observations), we thought it important to test whether a multimembrane spanning G protein-coupled receptor mutant might also be temperature sensitive.

To examine this question, three mutants LHRs were examined. Each of these mutants has been shown to be retained to some degree intracellularly, indicating that the mutations caused some degree of misfolding into the proteins. Nonetheless, as has been shown for other rLHR mutants where a binding site has not been disturbed, these intracellularly trapped mutants exhibited high affinity hCG binding, suggesting that the misfolding was not a gross alteration of conformation (9, 10, 12). Furthermore, the intracellular retention of these mutants does not appear to be a result of overexpression of the mutant proteins resulting in overloading the cellular processing system. As shown in Table 1Go, the cell lines expressing the mutants all had lower numbers of total rLHRs than rLHR(wt-18), which has a density of approximately 3,000–6,000 cell surface receptors per cell (9, 11, 24). As such, all the cell lines in this study expressed receptors at densities somewhat lower than gonadal cells expressing wild-type LHRs. Furthermore, for both the wild-type rLHR as well as rLHR(T175) and rLHR(K541, 544, 547) several different clones of cells were examined. For each kind of receptor, the absolute numbers of cell surface receptors varied greatly between clones; however, the percentage of receptor at the cell surface was similar. Therefore, the intracellular retention does not appear to be dependent upon receptor density. The experiments presented herein demonstrate that the rLHR mutants rLHR(T175A), rLHR(K541, 544, 547A), and rLHR(E441Q) are indeed temperature sensitive in that a greater percentage of receptor can be expressed on the cell surface if the cells are grown at reduced temperatures. In other studies, we have found that not all rLHR mutants that are trapped intracellularly are temperature sensitive (13). In general, it has been observed that if a mutant is profoundly trapped such that little or no cell surface binding activity is detected, then it is unlikely that reduced temperatures will shift a greater proportion of the mutant to the cell surface. For example, when deletions were made in portions of the extracellular loops of the rLHR, most of these mutants were expressed almost entirely intracellularly (where they exhibited high affinity hCG binding) and were not shifted to the cell surface after preincubations at 26 C (13). In another case, deletions were made of the individual leucine-repeats of the extracellular domain of the rLHR. Deletions of repeats 1, 2, 3, 4, 5, or 6 did not cause a loss of expression of receptor protein but did result in a complete loss of hormone binding activity in both intact and solubilized cells, suggesting that these deletions disrupted a hormone binding domain(s) (7). Preincubations of cells expressing any of these mutants did not cause binding activity to appear in either the intact or solubilized cells (unpublished data), presumably due to the conformational changes caused by such large deletions. In contrast to the above situations, if rLHR mutants are expressed to at least some degree at the cell surface at 37 C, then they generally do respond at least somewhat to the decreased temperatures. This trend is apparent within the three mutants examined herein in that rLHR(E441Q), which was trapped more extensively than the other two mutants, responded less well to the reduced temperatures. Therefore, we postulate that a decreased percentage of mutant receptor on the cell surface coupled with an inability to increase cell surface expression after preincubations at decreased temperatures is most likely indicative of more severe conformational changes imposed by the particular mutation.

The data presented herein demonstrate that preincubations of cells expressing either the wild-type or intracellularly retained mutant rLHRs at reduced temperatures causes an increase in the total number of rLHRs. Furthermore, for cells expressing intracellularly retained mutant rLHRs, the decreased temperatures increase the percentage of receptor at the cell surface. Thus, the overall efficiency of expression of a misfolded receptor is increased. At which stage of the folding/trafficking process the reduced temperatures have an effect has not yet been determined. Nor is it known how reduced temperatures aid in the folding of otherwise misfolded proteins. However, some important insights may be extrapolated from recent studies on the thermodynamic properties of CFTR({Delta}F508), which suggest that the mutation affects a step in the folding pathway rather than the protein’s stability (25). Hence, we speculate that those mutations of the rLHR that are temperature sensitive may similarly have affected residues that make important intramolecular contacts during the folding process of the molecule.

Mutants of the rLHR that are not expressed at the cell surface appear to be retained in the endoplasmic reticulum (ER) and/or cis-Golgi because they are sensitive to endoglycosidase H (14, 16). Because intracellularly retained rLHR mutants have been found to have a high affinity for hCG, it appears that by the time they exit the ER/cis-Golgi, they must have already assumed most if not all of their final conformation. Recent studies, however, have shown that the intracellularly retained rLHR mutants, like the precursor form of the wild-type rLHR, are not yet in the same conformation as the cell surface mature form of the receptor (13). This conclusion is based upon the observation that oLH, unlike hCG, binds the intracellular form of the rLHR with a reduced affinity as compared with the cell surface rLHR (13). Therefore, modifications to the tertiary structure of the rLHR must ensue after its exit from the ER/cis-Golgi that allow it to have the proper final conformation enabling plasma membrane insertion.

Mutations of G protein-coupled receptors that result in intracellular retention are not restricted to the rLHR. Indeed, when the same mutations causing intracellular retention of the rLHR have been introduced into the rFSHR, it has been shown that the rFSHR mutants are similarly retained intracellularly (14). However, unlike the rLHR, intracellularly retained mutants of the rFSHR are devoid of any hormone binding activity (14). The presence of high affinity hCG binding activity (with albeit decreased oLH binding activity) in intracellularly retained rLHR mutants, but the absence of any hormone binding activity in intracellular retained rFSHR mutants suggests a major difference in the temporal pattern of folding between the two gonadotropin receptors during their biosynthesis. Consistent with this hypothesis is the observation that whereas the newly synthesized rFSHR absolutely requires N-linked carbohydrates to fold into a conformation enabling the receptor to bind hormone (26), the rLHR does not strictly require N-linked carbohydrates for folding into its mature conformation (D. Davis and D. L. Segaloff, manuscript submitted). An interesting question is whether mutations of the rLHR and rFSHR, which cause intracellular retention, also cause intracellular retention of the closely related TSHR. Certainly, many mutants of the hTSHR have been shown to result in the absence of hormone binding activity on the cell surface (27, 28, 29). However, in the absence of binding assays to solubilized extracts or Western blots, it is not possible to conclude whether the absence of binding activity on the cell surface is due to intracellular retention of the mutants and/or decreased stability of the mutants. Similarly, certain mutations of several other G protein-coupled receptors have been shown to result in a decreased cell surface expression of the mutant receptor. Again, whether these result from decreased protein expression and/or decreased cell surface expression needs to be determined. It has, however, been clearly shown for adrenergic receptors (30) and rhodopsin (31) that some mutations do indeed result in intracellular retention of these G protein-coupled receptors.

As discussed above, cystic fibrosis is associated with mutations of the CFTR protein that prevent its normal cell surface expression (17). Other diseases, though, have also been associated with intracellular trapping of mutant cell surface receptors. For example, autosomal dominant retinitis pigmentosa has been shown to be associated in many cases with mutations causing single amino acid substitutions in rhodopsin that resulted in partial or extensive trapping of the mutants within the endoplasmic reticulum (31). Similarly, a large percentage of the mutations of the LDL receptor associated with familial hypercholesterolemia resulted in the intracellular retention of the mutant LDL receptors (32). Of particular relevance is the report of a naturally occurring mutations of the hLHR found in a patient with Leydig cell hypoplasia (33). In this case, the decreased cell surface expression of a LHR prematurely truncated in the fifth transmembrane helix appeared to be due at least in part to intracellular retention of the mutant receptor (33). It is not unreasonable to expect that many other naturally occurring mutations of the LHR would also lead to intracellular retention of the receptor and consequent impairment of reproductive function. For those mutations that are not affecting hormone binding or G protein-coupling per se, a therapeutic intervention that would increase the proper folding and targeting of the receptors to the plasma membrane would be predicted to be sufficient for conferring responsiveness of the gonadal cell. As such, it will be important to more fully understand the normal processes of folding, posttranslational processing, and cell surface targeting of the LHR.


    Acknowledgments
 
We wish to thank Dr. Mario Ascoli for helpful discussions and for critically reading the manuscript.


    Footnotes
 
1 These studies were supported by NIH Grant HD-22196 (to D.L.S.). The services and facilities provided by the University of Iowa Diabetes and Endocrinology Research Center Grant DK-25295 are also gratefully acknowledged. Back

2 Recipient of NIH Research Career Development Award HD-00968. Back

Received July 18, 1996.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Gudermann T, Birnbaumer M, Birnbaumer L 1992 Evidence for dual coupling of the murine luteinizing hormone receptor to adenylyl cyclase and phosphoinositide breakdown and Ca+2 mobilization. J Biol Chem 267:4479–4488[Abstract/Free Full Text]
  2. McFarland KC, Sprengel R, Phillips HS, Kohler M, Rosemblit N, Nikolics K, Segaloff DL, Seeburg PH 1989 Lutropin-choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family. Science 245:494–499[Abstract/Free Full Text]
  3. Xie YB, Wang H, Segaloff DL 1990 Extracellular domain of lutropin/choriogonadotropin receptor expressed in transfected cells binds choriogonadotropin with high affinity. J Biol Chem 265:21411–21414[Abstract/Free Full Text]
  4. Thomas DM, Segaloff DL 1994 Hormone binding properties and glycosylation pattern of a recombinant form of the extracellular domain of the LH/CG receptor exressed in mammalian cells. Endocrinology 135:1902–1912[Abstract]
  5. Tsai-Morris CH, Buczko E, Wang W, Dufau ML 1990 Intronic nature of the rat luteinizing hormone receptor gene defines a soluble receptor subspecies with hormone binding activity. J Biol Chem 265:19385–19388[Abstract/Free Full Text]
  6. Ji I, Ji TH 1991 Exons 1–10 of the rat LH receptor encode a high affinity hormone binding site and exon 11 encodes G-protein modulation and a potential second hormone binding site. Endocrinology 128:2648–2650[Abstract/Free Full Text]
  7. Thomas D, Rozell TG, Liu X, Segaloff DL 1996 Mutational analyses of the extracellular domain of the full-length lutropin/choriogonadotropin receptor suggest leucine-rich repaets 1–6 are involved in hormone binding. Mol Endocrinol 10:760–768[Abstract/Free Full Text]
  8. Segaloff DL, Ascoli M 1993 The lutropin/choriogonadotropin (LH/CG) receptor-4 years later. Endocrine Rev 14:324–347[Abstract/Free Full Text]
  9. Wang H, Jaquette J, Collison K, Segaloff DL 1993 Positive charges in a putative amphiphilic helix in the carboxyl-terminal region of the third intracellular loop of the luteinizing hormone/chorionic gonadotropin receptor are not required for hormone-stimulated cAMP production but are necessary for expression of the receptor at the plasma membrane. Mol Endocrinol 7:1437–1444[Abstract/Free Full Text]
  10. Wang Z, Wang H, Ascoli M 1993 Mutation of a highly conserved acidic residue present in the second intracellular loop of G-protein-coupled receptors does not impair hormone binding or signal transduction of the luteinizing hormone/chorionic gonadotropin receptor. Mol Endocrinol 7:85–93[Abstract/Free Full Text]
  11. Zhu H, Wang H, Ascoli M 1995 The lutropin/choriogonadotropin receptor is palmitoylated at intracellular cysteine residues. Mol Endocrinol 9:141–150[Abstract/Free Full Text]
  12. Liu X, Davis D, Segaloff DL 1993 Disruption of potential sites for N-linked glycosylation does not impair hormone binding to the lutropin/choriogonadotropin receptor if Asn 173 is left intact. J Biol Chem 268:1513–1516[Abstract/Free Full Text]
  13. Abell A, Liu X, Segaloff DL 1996 Deletions of portions of the extracellular loops of the lutropin/choriogonadotropin receptor decrease the binding affinity for oLH, but not hCG, by preventing the formation of mature cell surface receptor. J Biol Chem 271:4518–4527[Abstract/Free Full Text]
  14. Rozell TG, Wang H, Liu X, Segaloff DL 1995 Intracellular retention of mutant gonadotropin receptors results in loss of hormone binding activity of the follitropin receptor but not the lutropin/choriogonadotropin receptor. Mol Endocrinol 9:1727–1736[Abstract/Free Full Text]
  15. Quintana J, Wang H, Ascoli M 1993 The regulation of the binding affinity of the lutropin/choriogonadotropin receptor by sodium ions is mediated by a highly conserved aspartate located in the second transmembrane domain of G protein-coupled receptors. Mol Endocrinol 7:767–775[Abstract/Free Full Text]
  16. Zhu X, Gudermann T, Birnbaumer M, Birnbaumer L 1993 A luteinizing hormone receptor with a severely truncated cytoplasmic tail (LHR-ct628) desensitizes to the same degree as the full-length receptor. J Biol Chem 268:1723–1728[Abstract/Free Full Text]
  17. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O’Riordan CR, Smith AE 1990 Defective intracellular transport and processing of CFTR is the molecular basis for most cystic fibrosis. Cell 63:827–834[CrossRef][Medline]
  18. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ 1992 Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358:761–764[CrossRef][Medline]
  19. Roche PC, Bergert ER, Ryan RJ 1985 A simple and rapid method using polyethylenemine-treated filters for assay of solubilized LH/hCG receptors. Endocrinology 117:790–792[Abstract/Free Full Text]
  20. Munson PJ, Rodbard D 1980 LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220–239[CrossRef][Medline]
  21. Ascoli M, Puett D 1978 Gonadotropin binding and stimulation of steroidogenesis in Leydig tumor cells. Proc Natl Acad Sci (USA) 75:99–102[Abstract/Free Full Text]
  22. Whaley BS, Yuan N, Birnbaumer L, Clark RB, Barber R 1994 Differential expression of the ß-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative evaluation. Mol Pharmacol 45:481–489[Abstract]
  23. Rose JK, Machamer CE 1988 Vesicular stomatitis virus G proteins with altered glycosylation sites display temperature-sensitive intracellular transport and are subject to aberrant intermolecular disulfide bonding. J Biol Chem 263:5955–5960[Abstract/Free Full Text]
  24. Dhanwada KR, Vijapurkar U, Ascoli M 1996 Two mutations of the lutropin/choriogonadotropin receptor that impair signal transduction also interfere with receptor-mediated endocytosis. Mol Endocrinol 10:544–554[Abstract/Free Full Text]
  25. Qu B-H, Thomas PJ 1996 Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway. J Biol Chem 271:7261–7264[Abstract/Free Full Text]
  26. Davis D, Liu X, Segaloff DL 1995 Identification of the sites of N-linked glycosylation on the follicle-stimulating hormone (FSH) receptor and assessment of their role in FSH receptor function. Mol Endocrinol 9:159–170.[Abstract/Free Full Text]
  27. Wadsworth H, Russo D, Nagayama Y, Chazenbalk GD, Rapoport B 1992 Studies on the role of amino acids 38–45 in the expression of a functional thyrotropin receptor. Mol Endocrinol 6:394–398[Abstract/Free Full Text]
  28. Wadsworth HL, Chazenbalk GD, Nagayam Y, Russo D, Rapoport B 1990 An insertion in the human thyrotropin receptor critical for high affinity hormone binding. Science 249:1423–1425[Abstract/Free Full Text]
  29. Russo D, Chazenbalk GD, Nagayama Y, Wadsworth HL, Rapoport B 1991 Site-directed mutagenesis of the human thyrotropin receptor: role of asparagine-linked oligosaccharides in the expression of a functional receptor. Mol Endocrinol 5:29–33[Abstract/Free Full Text]
  30. Suryanarayana S, von Zastrow M, Kobilka BK 1992 Identification of intramolecular interactions in adrenergic receptors. J Biol Chem 267:21991–21994[Abstract/Free Full Text]
  31. Sung CH, Schneider BG, Agarwal N, Papermaster DS, Nathans J 1991 Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci USA 88:8840–8844[Abstract/Free Full Text]
  32. Hobbs HH, Russell DW, Brown MS, Goldstein JL 1990 The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24:133–170[CrossRef][Medline]
  33. Laue L, Wu SM, Kudo M, Hsueh AJW, Cutler Jr GB, Griffin JE, Wilson JD, Brain C, Berry AC, Grant DB, Chan WY 1995 A nonsense mutation of the human luteinizing hormone receptor gene in Leydig cell hypoplasia. Hum Mol Genet 4:1429–1433[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
N. V. Bogatcheva, A. Ferlin, S. Feng, A. Truong, L. Gianesello, C. Foresta, and A. I. Agoulnik
T222P mutation of the insulin-like 3 hormone receptor LGR8 is associated with testicular maldescent and hinders receptor expression on the cell surface membrane
Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E138 - E144.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
D. Mizrachi and D. L. Segaloff
Intracellularly Located Misfolded Glycoprotein Hormone Receptors Associate with Different Chaperone Proteins than Their Cognate Wild-Type Receptors
Mol. Endocrinol., July 1, 2004; 18(7): 1768 - 1777.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y.-X. Tao, N. B. Johnson, and D. L. Segaloff
Constitutive and Agonist-dependent Self-association of the Cell Surface Human Lutropin Receptor
J. Biol. Chem., February 13, 2004; 279(7): 5904 - 5914.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. M. Tan, H. H. Nickols, and L. E. Limbird
Appropriate Polarization following Pharmacological Rescue of V2 Vasopressin Receptors Encoded by X-linked Nephrogenic Diabetes Insipidus Alleles Involves a Conformation of the Receptor That Also Attains Mature Glycosylation
J. Biol. Chem., September 12, 2003; 278(37): 35678 - 35686.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. M. Kubiak, M. J. Larsen, S. C. Nulf, M. R. Zantello, K. J. Burton, J. W. Bowman, T. Modric, and D. E. Lowery
Differential Activation of "Social" and "Solitary" Variants of the Caenorhabditis elegans G Protein-coupled Receptor NPR-1 by Its Cognate Ligand AF9
J. Biol. Chem., September 5, 2003; 278(36): 33724 - 33729.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Hirakawa, C. Galet, and M. Ascoli
MA-10 Cells Transfected with the Human Lutropin/Choriogonadotropin Receptor (hLHR): A Novel Experimental Paradigm to Study the Functional Properties of the hLHR
Endocrinology, March 1, 2002; 143(3): 1026 - 1035.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
U. E. Petaja-Repo, M. Hogue, A. Laperriere, P. Walker, and M. Bouvier
Export from the Endoplasmic Reticulum Represents the Limiting Step in the Maturation and Cell Surface Expression of the Human delta Opioid Receptor
J. Biol. Chem., April 28, 2000; 275(18): 13727 - 13736.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. G. Rozell, D. P. Davis, Y. Chai, and D. L. Segaloff
Association of Gonadotropin Receptor Precursors with the Protein Folding Chaperone Calnexin
Endocrinology, April 1, 1998; 139(4): 1588 - 1593.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. C. Latronico, Y. Chai, I. J.P. Arnhold, X. Liu, B. B. Mendonca, and D. L. Segaloff
A Homozygous Microdeletion in Helix 7 of the Luteinizing Hormone Receptor Associated with Familial Testicular and Ovarian Resistance Is Due to Both Decreased Cell Surface Expression and Impaired Effector Activation by the Cell Surface Receptor
Mol. Endocrinol., March 1, 1998; 12(3): 442 - 450.
[Abstract] [Full Text]


Home page
J. Neurosci.Home page
P. L. Durham, R. V. Sharma, and A. F. Russo
Repression of the Calcitonin Gene-Related Peptide Promoter by 5-HT1 Receptor Activation
J. Neurosci., December 15, 1997; 17(24): 9545 - 9553.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaquette, J.
Right arrow Articles by Segaloff, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaquette, J.
Right arrow Articles by Segaloff, D. L.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals